Visual Performance of Soft Contact Lenses With Myopia Control Optics

NCT05141448 | Completed Results

• 1 other identifier: CR-6457
• Study Type: interventional
• Target: 79
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multi-site, bilateral, dispensing, randomized, controlled, single-masked, 3x3 crossover study with a run-in period.

Conditions

Visual Acuity

Outcome Measures

Primary Outcomes (1)

• Binocular Visual Performance (LogMAR)

  Visual performance was calculated as binocular contact lens-corrected distance visual acuity using a Logarithm of Minimal Angle of Resolution (logMAR) visual acuity scale. This was evaluated under high luminance and high contrast conditions (HLHC) at 4 meters from Early Treatment Diabetic Retinopathy Study (ETDRS) charts at the 2-week follow-up visit. Lower visual performance values indicate better vision. A value of 0.0 logMAR is equivalent to 20/20 Snellen Visual Acuity. The average visual performance was reported for each lens type. Binocular visual performance for Run-in lens was measured at 1-week follow-up visit.

  Up to 2-Week Follow-up

Study Arms (6)

Test1/Test2/Control

EXPERIMENTAL

Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Test1/Test2/Control.

Device: 1-Day Acuvue Moist; Device: EMO-118; Device: EMO-114; Device: MiSight® 1 day

Test1/Control/Test2

EXPERIMENTAL

Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Test1/Control/Test2.

Device: 1-Day Acuvue Moist; Device: EMO-118; Device: EMO-114; Device: MiSight® 1 day

Test2/Test1/Control

EXPERIMENTAL

Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Test2/Test1/Control.

Device: 1-Day Acuvue Moist; Device: EMO-118; Device: EMO-114; Device: MiSight® 1 day

Test2/Control /Test1

EXPERIMENTAL

Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Test2/Control /Test1.

Device: 1-Day Acuvue Moist; Device: EMO-118; Device: EMO-114; Device: MiSight® 1 day

Control/Test1/Test2

EXPERIMENTAL

Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Control/Test1/Test2.

Device: 1-Day Acuvue Moist; Device: EMO-118; Device: EMO-114; Device: MiSight® 1 day

Control/Test2/Test1

EXPERIMENTAL

Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Control/Test2/Test1.

Device: 1-Day Acuvue Moist; Device: EMO-118; Device: EMO-114; Device: MiSight® 1 day

Interventions

1-Day Acuvue Moist DEVICE

Run-in Contact Lens

Control/Test1/Test2; Control/Test2/Test1; Test1/Control/Test2; Test1/Test2/Control; Test2/Control /Test1; Test2/Test1/Control

EMO-118 DEVICE

Test Lens1

Control/Test1/Test2; Control/Test2/Test1; Test1/Control/Test2; Test1/Test2/Control; Test2/Control /Test1; Test2/Test1/Control

EMO-114 DEVICE

Test Lens2

Control/Test1/Test2; Control/Test2/Test1; Test1/Control/Test2; Test1/Test2/Control; Test2/Control /Test1; Test2/Test1/Control

MiSight® 1 day DEVICE

Control Lens

Control/Test1/Test2; Control/Test2/Test1; Test1/Control/Test2; Test1/Test2/Control; Test2/Control /Test1; Test2/Test1/Control

Eligibility Criteria

• Age: 7 Years - 17 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Potential subjects must satisfy all of the following criteria to be enrolled in the study:
• Read (or be read to) and sign the CHILDREN'S ASSENT (Information and Assent Form) and receive a fully executed copy of the form.
• Have parents or legal guardians who must read, understand, and sign the STATEMENT OF INFORMED CONSENT (Parental Permission Form and Authorization to Use and Disclose Medical Information).
• Appear able and willing to adhere to the instructions set forth in this clinical protocol.
• Be between 7 and 17 (inclusive) years of age at the time of screening.
• By self-report, habitually wear soft contact lenses or be a current non-contact lens wearer interested in soft lens wear.
• The non-vertex corrected best sphere distance refraction must be between -1.00 D and -4.50 D (inclusive) in each eye.
• The magnitude of the cylindrical component of the subject's vertex-corrected distance refraction must be less than or equal to 0.75 D (inclusive) in each eye with any degree of axis.
• The distance visual acuity with best sphere distance correction must be 20/25 or better in each eye.
• Have ≤ 1.50 D difference in subjective best-sphere refraction between the two eyes.
• Have 20/40 or better vision in each eye with wearable spectacles or uncorrected.

You may not qualify if:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:
• Be currently pregnant or lactating.
• Be diabetic.
• Be currently using any ocular medications. Lubricants (artificial tears) eyedrops are allowed.
• Have any current ocular infection of any type.
• Have any systemic disease (e.g., Sjogren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g., rheumatoid arthritis), any underlying medical condition that makes subjects at risk of severe COVID complications, a history of serious mental illness or seizures, or other diseases, by parent or legal guardian's self-report, which are known to interfere with contact lens wear and/or participation in the study.
• Use of systemic medication (e.g., chronic steroid use) that are known to interfere with contact lens wear and/or participation in the study. See section 9.1 for additional details regarding excluded systemic medications.
• Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 30 days.
• Be currently wearing lenses in an extended wear modality.
• Be currently wearing soft contact lenses for astigmatism in either eye.
• Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment.
• Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
• Children who are wards of the State or any other agency, institution, or entity.
• Have any ocular allergies, infections, or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but is not limited to, entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis.
• Have grade 3 or greater palpebral conjunctival observations or any other grade 2 slit lamp findings on the ISO 11980 classification scale.

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (1)

Vision Optique

Houston, Texas, 77005, United States

Location

Results Point of Contact

• Title: Principal Research Optometrist
• Organization: Johnson & Johnson Vision Care, Inc. (JJVC)

anixon1@its.jnj.com

614-531-6781

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 19, 2021
• First Posted: December 2, 2021
• Study Start: November 22, 2021
• Primary Completion: April 1, 2022
• Study Completion: April 1, 2022
• Last Updated: April 27, 2025
• Results First Posted: April 8, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will share

Locations

US (1)